Işıl ÇAKIR
(Kayseri Şehir Hastanesi, Biyokimya Bölümü, Kayseri, Türkiye)
Hasan Basri ARİFOĞLU
(Okan Üniversitesi Hastanesi, Oftalmoloji Bölümü, İstanbul, Türkiye)
Nahide GÜNAY
(Kayseri Şehir Hastanesi, Biyokimya Bölümü, Kayseri, Türkiye)
Emine PANGAL
(Kayseri Şehir Hastanesi, Oftalmoloji Bölümü, Kayseri, Türkiye)
Derya ŞAHİN
(Dr.Abdurrahman Yurtaslan Ankara Eğitim ve Araştırma Hastanesi, Dahili Tıp Bölümü, Ankara, Türkiye)
Gökçen ALICI SERT
(Kayseri Şehir Hastanesi, Biyokimya Bölümü, Kayseri, Türkiye)
Necati DURU
(Kayseri Şehir Hastanesi, Oftalmoloji Bölümü, Kayseri, Türkiye)
Yıl: 2020Cilt: 42Sayı: 2ISSN: 2149-2247 / 2149-2549Sayfa Aralığı: 190 - 194İngilizce

105 0
Monocyte to High-Density Lipoprotein Ratio: A Novel Inflammation Marker Related to Diabetic Retinopathy
Objective: The most common microvascular complication of diabetes is diabetic retinopathy (DR). A new and recentlyemerged marker of oxidative stress and inflammation is monocyte to high-density lipoprotein cholesterol ratio (MHR).Platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) have also been shown as they are biomarkers ofsystemic inflammation in various diseases. The present study aims to assess MHR, its predictive value and relations betweenother inflammation markers in DR patients.Materials and Methods: Sixty-eight patients with DR, fifty-four DM patients without DR and forty-two control subjectswere included in this study. Complete blood count, lipoprotein and uric acid levels were recorded. MHR was calculated.Results: MHR, NLR and PLR were statistically significantly higher in DR group than DM without DR group (p=0.008,p=0.042, p=0.003, respectively). Then, receiver operating characteristic (ROC) curve analysis was performed and pointedthat MHR predicted DR using a cut-off level of 0.0156 with 63% sensitivity and 76% specificity.Conclusion: In this study, we investigated MHR in DR patients and its relationship with other inflammatory markers,lipoproteins and uric acid. We suggested that an elevated admission of MHR may be of benefit to detect DR and to determinethe CVD risk of these patients.
DergiAraştırma MakalesiErişime Açık
  • 1. Li J, Cao Y, Liu W, Liu W, Wang Q, Qian Y, Lu P. Correlations among Diabetic Microvascular Complications: A Systematic Review and Metaanalysis. Sci Rep 2019; 9: 3137.
  • 2. Warwick AN, Brooks AP, Osmond C, Krishnan R, Medscape. Prevalence of referable, sight-threatening retinopathy in type 1 diabetes and its relationship to diabetes duration and systemic risk factors. Eye (Lond) 2017; 31(2): 333–41.
  • 3. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35(3): 556–64.
  • 4. Nowak M, Wielkoszyński T, Marek B, Kos-Kudła B, Swietochowska E, Siemińska L, et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med 2010; 10(3): 185–92.
  • 5. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog Retin Eye Res 2009; 28(5): 348–68.
  • 6. Tomić M, Ljubić S, Kastelan S. The role of inflammation and endothelial dysfunction in the pathogenesis of diabetic retinopathy. Coll Antropol 2013; 37 Suppl 1: 51–7.
  • 7. Davidson WS, Shah AS. High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes. Methodist Debakey Cardiovasc J 2019; 15(1): 55–61.
  • 8. Rye KA. High density lipoprotein structure, function, and metabolism: a new Thematic Series. J Lipid Res 2013; 54(8): 2031–3.
  • 9. Park BK, Park JW, Han EC, Ryoo SB, Han SW, Kim TY, et al. Systemic inflammatory markers as prognostic factors in stage IIA colorectal cancer. J Surg Oncol 2016; 114(2): 216–21.
  • 10. Wu Y, Chen Y, Yang X, Chen L, Yang Y. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. Int Immunopharmacol 2016; 36: 94–9.
  • 11. Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014; 46(8): 1619–25.
  • 12. Kundi H, Kiziltunc E, Cetin M, Cicekcioglu H, Cetin ZG, Cicek G, et al. Association of monocyte/HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease. Herz 2016; 41(6): 523–9.
  • 13. Akboga MK, Yayla C, Balci KG, Ozeke O, Maden O, Kisacik H, et al. Relationship between Serum Albumin Level and Monocyte-to-HighDensity Lipoprotein Cholesterol Ratio with Saphenous Vein Graft Disease in Coronary Bypass. Thorac Cardiovasc Surg 2017; 65(4): 315–21.
  • 14. Zhang Y, Li S, Guo YL, Wu NQ, Zhu CG, Gao Y, et al. Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Ann Med 2016; 48(5): 305–12.
  • 15. Karatas A, Turkmen E, Erdem E, Dugeroglu H, Kaya Y. Monocyte to high-density lipoprotein cholesterol ratio in patients with diabetes mellitus and diabetic nephropathy. Biomark Med 2018; 12(9): 953–9.
  • 16. Haghikia A, Landmesser U. High-Density Lipoproteins: Effects on Vascular Function and Role in the Immune Response. Cardiol Clin 2018; 36(2): 317–27.
  • 17. Gratchev A, Sobenin I, Orekhov A, Kzhyshkowska J. Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiology 2012; 217(5): 476–82.
  • 18. Kuwabara M. Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse (Basel) 2016; 3(3-4): 242–52.
  • 19. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol 2012; 59(3): 235–42.
  • 20. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008; 58(2): 623–30.
  • 21. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009; 61(2): 225–32.
  • 22. Sluijs I, Beulens JW, van der A DL, Spijkerman AM, Schulze MB, van der Schouw YT. Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. J Nutr 2013; 143(1): 80–5.
  • 23. Wang T, Bi Y, Xu M, Huang Y, Xu Y, Li X, et al. Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese. Endocrine 2011; 40(1): 109–16.
  • 24. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008; 31(2): 361–2.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.